%PDF-1.3
%
22 0 obj
<>>>/BBox[0 0 612 792]/Length 55>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
33 0 obj
<>>>/BBox[0 0 612 792]/Length 54>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
7 0 obj
<>>>/BBox[0 0 612 792]/Length 55>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
3 0 obj
<>>>/BBox[0 0 612 792]/Length 54>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
26 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
21 0 obj
<>>>/BBox[0 0 612 792]/Length 54>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
27 0 obj
<>>>/BBox[0 0 612 792]/Length 54>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
24 0 obj
<>>>/BBox[0 0 612 792]/Length 54>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
11 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
19 0 obj
<>>>/BBox[0 0 612 792]/Length 55>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
28 0 obj
<>>>/BBox[0 0 612 792]/Length 55>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
17 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
32 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
9 0 obj
<>>>/BBox[0 0 612 792]/Length 54>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
31 0 obj
<>>>/BBox[0 0 612 792]/Length 55>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
35 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
8 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
23 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
12 0 obj
<>>>/BBox[0 0 612 792]/Length 54>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
34 0 obj
<>>>/BBox[0 0 612 792]/Length 55>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
6 0 obj
<>>>/BBox[0 0 612 792]/Length 54>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
29 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
4 0 obj
<>>>/BBox[0 0 612 792]/Length 55>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
37 0 obj
<>>>/BBox[0 0 612 792]/Length 55>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
18 0 obj
<>>>/BBox[0 0 612 792]/Length 54>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
13 0 obj
<>>>/BBox[0 0 612 792]/Length 55>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
25 0 obj
<>>>/BBox[0 0 612 792]/Length 55>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
10 0 obj
<>>>/BBox[0 0 612 792]/Length 55>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
14 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
20 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
30 0 obj
<>>>/BBox[0 0 612 792]/Length 54>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
1 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
15 0 obj
<>>>/BBox[0 0 612 792]/Length 54>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
5 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
16 0 obj
<>>>/BBox[0 0 612 792]/Length 55>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
36 0 obj
<>>>/BBox[0 0 612 792]/Length 54>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
39 0 obj
<>stream
Acrobat Distiller 8.1.0 (Windows); modified using iText 4.2.0 by 1T3XT
Arbortext Advanced Print Publisher 9.0.114/W
2016-10-19T07:39:55-07:00
2015-01-03T17:12:20+05:30
application/pdf
untitled
uuid:738b6d26-4907-4bdb-8ff1-8cb74e92d0a9
uuid:4caafd89-3a53-4293-884f-f6034ad4528b
endstream
endobj
40 0 obj
<>stream
x+ |
endstream
endobj
41 0 obj
<>stream
xS**T0T0 BiUD* 8
endstream
endobj
42 0 obj
<>stream
x+ |
endstream
endobj
43 0 obj
<>stream
xS**T0T0 Bih]D. r^j
endstream
endobj
44 0 obj
<>stream
x+ |
endstream
endobj
45 0 obj
<>stream
xS**T0T0 Bih] D. pa
endstream
endobj
46 0 obj
<>stream
x+ |
endstream
endobj
47 0 obj
<>stream
xS**T0T0 Bil])D. qgj
endstream
endobj
48 0 obj
<>stream
x+ |
endstream
endobj
49 0 obj
<>stream
xS**T0T0 Bid]D. qdj
endstream
endobj
50 0 obj
<>stream
x+ |
endstream
endobj
51 0 obj
<>stream
xS**T0T0 Bid]%D. rs
endstream
endobj
52 0 obj
<>stream
x+ |
endstream
endobj
53 0 obj
<>stream
xS**T0T0 Bid]1D. pa
endstream
endobj
54 0 obj
<>stream
x+ |
endstream
endobj
55 0 obj
<>stream
xS**T0T0 BiU !D. _e1
endstream
endobj
56 0 obj
<>stream
x+ |
endstream
endobj
57 0 obj
<>stream
xS**T0T0 Bil]D. pa
endstream
endobj
58 0 obj
<>stream
x+ |
endstream
endobj
59 0 obj
<>stream
xS**T0T0 BiU)D* 9V
endstream
endobj
60 0 obj
<>stream
x+ |
endstream
endobj
61 0 obj
<>stream
xS**T0T0 Bih]9D. qaj
endstream
endobj
62 0 obj
<>stream
x+ |
endstream
endobj
63 0 obj
<>stream
xS**T0T0 BiUD* :
endstream
endobj
65 0 obj
<>stream
/GS1 gs
BT
/F4 1 Tf
9.843 0 0 9.843 62.022 725.1588 Tm
0 0 0 1 k
0 Tc
0 Tw
[(virus)-529.5(after)-526.3(stopping)-527.3(therapy)-528.5(at)-527.6(176)-527.4(days)-529.5(postinfection.)]TJ
7.3823 0 0 6.5614 293.7259 729.5242 Tm
(34)Tj
9.843 0 0 9.843 62.022 714.1605 Tm
[(However,)-372.3(later)-365.2(analysis)-368.1(showed)-371.3(that)-368.7(this)-367.3(subject)-367.2(possessed)]TJ
0 -1.1116 TD
[(the)-661.2(protective)-665.7(human)-658.7(leukocyte)-664.5(antigen)-661.1(B57,)-658.6(naturally)]TJ
T*
[(associated)-447.5(with)-443.3(spontaneous)-440.4(control,)-444.5(calling)-442.4(into)-442.4(question)]TJ
T*
[(whether)-310.5(this)-309.7(individual)-312.2(would)-306(have)-312(controlled)-307.4(viral)-312.2(replica-)]TJ
0 -1.1174 TD
[(tion)-580.6(spontaneously)-581(even)-576.9(in)-578.3(the)-580.6(absence)-582.4(of)-578.1(a)-578.2(scheduled)]TJ
0 -1.1116 TD
[(treatment)-285.7(interruption.)]TJ
7.3823 0 0 6.5614 151.3133 663.7605 Tm
(35)Tj
9.843 0 0 9.843 72 648.4534 Tm
[(However,)-493.2(the)-488.4(VISCONTI)-491.5(study)-489.3(group)-483.5(showed)-492.3(a)-486.1(more)]TJ
-1.0137 -1.1174 TD
[(generalizable)-269.3(success.)-267.5(Fourteen)-270.3(patients)-264.8(\()]TJ
/F10 1 Tf
16.6916 0 TD
(*)Tj
/F4 1 Tf
1.0022 0 TD
[(15%\))-264.6(treated)-264.9(for)]TJ
-17.6938 -1.1116 TD
[(36)-192.3(months)-192.1(following)-189.7(acute)-193.4(HIV)-189.3(infection)-196.9(were)-191.9(identied)-191(who)]TJ
T*
[(controlled)-307.4(their)-312.2(own)-303.7(viremia)-311(for)-302.7(24)-307.5(months)-307.3(following)-310.6(treat-)]TJ
0 -1.1174 TD
[(ment)-421.6(cessation.)]TJ
7.3823 0 0 6.5614 124.611 608.9951 Tm
(33)Tj
9.843 0 0 9.843 136.1196 604.5731 Tm
[(Interestingly,)-417.8(none)-420.3(of)-416.9(these)-422.5(subjects)-419.9(ex-)]TJ
-7.5279 -1.1116 TD
[(hibited)-372.1(protective)-372(HLA-class)-372(I)-363.9(alleles,)-371.9(arguing)-371.8(that)-368.7(control)]TJ
T*
[(was)-627.2(unlinked)-626.5(from)-627.6(any)-626.5(previously)-622.7(dened)-630.8(host-genetic)]TJ
T*
[(marker)-465.1(associated)-470.6(with)-466.3(natural)-465.3(robust)-467.3(control)-464.1(of)-468.7(viremia.)]TJ
0 -1.1174 TD
[(However,)-297.4(unlike)-290.3(HIV)-293(controllers,)-294.5(post-treatment)-296.9(controllers)]TJ
0 -1.1116 TD
[(had)-407.6(limited)-408(HIV-specic)-414.5(CD8)-408.4(T)-405.5(cell)-404.4(responses)-414.8(and)-401.9(lower)]TJ
T*
[(levels)-354.6(of)-353.5(CD8)-350.8(T)-353.6(cell)-352.6(activation,)-358.3(arguing)-354.6(that)-351.4(other)-358.1(arms)-352.1(of)]TJ
0 -1.1174 TD
[(the)-188.9(immune)-188.9(response)-189.3(may)-184.2(have)-191(collaborated)-191(or)-186.5(contributed)-187.6(to)]TJ
0 -1.1116 TD
[(the)-355.9(ability)-355(of)-353.5(these)-359.1(subjects)-356.6(to)-353.7(gain)-357(control)-354.7(over)-356.9(their)-352.5(viral)]TJ
T*
(infection.)Tj
/F3 1 Tf
8.9663 0 0 8.9663 62.022 484.0439 Tm
[(Shock)-334.2(and)-338.2(Kill)]TJ
/F11 1 Tf
0 -1.8336 TD
[(T)-334.4(cells)]TJ
/F4 1 Tf
9.843 0 0 9.843 72 451.1621 Tm
[(Among)-266.8(the)-263.8(potential)-266.2(shock)-265.7(and)-263.6(kill)-264(strategies,)-271.3(activated)-268.4(T)]TJ
-1.0137 -1.1116 TD
[(cells)-278.6(have)-277.4(recently)-277.5(been)-277.4(shown)-276.9(to)-273(efciently)-279.6(kill)-275.5(reactivated)]TJ
T*
(cells,)Tj
7.3823 0 0 6.5614 82.6582 433.644 Tm
(24)Tj
9.843 0 0 9.843 93.9968 429.2786 Tm
[(suggesting)-409.5(that)-403.2(a)-405.4(therapeutic)-408.8(vaccination)-408.8(approach)]TJ
-3.2485 -1.1174 TD
[(able)-283.3(to)-278.8(boost)-281.9(cytotoxic)-283.3(T)-278.8(cell)-283.5(activity)-282.4(may)-282.2(help)-282.2(promote)-280.9(the)]TJ
0 -1.1116 TD
[(eradication)-253.3(of)-249.8(the)-246.5(pool)-246.4(of)-249.8(latently)-247.8(infected)-254.4(cells.)-247.5(Along)-248.4(these)]TJ
T*
[(lines,)-522.8(the)-523(SIV)-528.1(protein-expressing)-524.3(rhesus)-525.7(cytomegalovirus)]TJ
0 -1.1174 TD
[(\(RhCMV/SIV\))-512.1(vector)-504.4(drove)-507.7(progressive)-509.5(clearance)-512.3(of)-503.3(the)]TJ
0 -1.1116 TD
[(virus,)-561.8(despite)-563(initial)-562.4(infection)-559.8(with)-558.5(the)-563.3(pathogenic)-561.9(SIV-)]TJ
T*
[(mac239)-183(strain.)]TJ
7.3823 0 0 6.5614 119.5086 367.8802 Tm
(3)Tj
9.843 0 0 9.843 125.0078 363.5149 Tm
[(This)-178.3(CMV)-184.7(vaccine-mediated)-194.4(eradication)-184.2(was)]TJ
-6.399 -1.1174 TD
[(linked)-526.4(to)-526.5(the)-528.7(elevated)-532.1(and)-522.8(durable)-528.5(induction)-529.8(of)-526.3(effector)]TJ
0 -1.1116 TD
[(memory)-217.6(T)-209.6(cell)-220.1(responses)-213.2(that)-218.9(were)-214.9(maintained)-217.7(at)-216.6(persistently)]TJ
T*
[(high)-390.4(levels)-394.9(due)-396.1(to)-394(the)-390.5(continual)-398.5(replication)-396.2(of)-388.1(the)-396.2(vaccine)]TJ
T*
[(vector.)-571.2(These)-567.5(data)-565.5(strongly)-573.3(suggest)-567.3(that)-564.5(a)-566.7(T)-566.7(cell-based)]TJ
0 -1.1174 TD
[()50.8(shock)-381.9(and)-378.8(kill)46()-381.2(strategy)-379.8(will)-380(likely)-382.5(require)-384.5(the)-379(induction)]TJ
0 -1.1116 TD
[(and)-528.6(sustenance)-533.8(of)-526.3(high)-528.7(levels)-533.1(of)-526.3(killer)-532.3(effector)-530.7(T)-526.4(cells.)]TJ
T*
[(However,)-476(T)-468.8(cell-based)-476.5(strategies)-475.2(are)-472.1(limited)-471.4(by)-468.7(potential)]TJ
0 -1.1174 TD
[(archived)-507.7(viral)-502.2(escape)-506.4(mutants,)-503.2(with)-500.9(potential)-508.1(irreversible)]TJ
0 -1.1116 TD
[(T)-457.3(cell)-462(exhaustion)-462.7(resulting)-460.5(in)-457.3(compromised)-460.3(killing)-463.2(activ-)]TJ
T*
[(ity,)-335.3(qualitative)-338.8(differences)-333.4(in)-336.4(vaccine-induced)-340.5(immunity)-334.2(by)]TJ
0 -1.1174 TD
[(polymorphic)-222.1(major)-215.3(histocompatibility)-220.1(complex)-218.8(\()-87.5(MHC\))-214.5(class)]TJ
0 -1.1116 TD
[(I)-283.3(alleles,)-291.3(and)-280.9(issues)-289.5(related)-287.9(to)-284.6(T)-284.5(cell)-283.5(homing)-284.4(to)-284.6(sites)-283(of)-284.4(viral)]TJ
T*
(latency.)Tj
1.0137 -1.1174 TD
[(Moreover,)-453.2(to)-451.6(date,)-453.8(therapeutic)-454.9(vaccine)-450.2(efforts)-458(have)-450.2(fo-)]TJ
-1.0137 -1.1116 TD
[(cused)-238(on)-232.6(inducing)-234.9(cytotoxic)-237.3(T)-238.4(cell)-231.6(respon)-7.5(ses;)-235.7(however,)-233.2(most)]TJ
T*
[(have)-565.4(shown)-559.1(a)-560.9(limited)-563.6(capacity)-566.7(to)-561(impact)-563.4(viral)-565.6(rebound)]TJ
T*
(meaningfully.)Tj
7.3823 0 0 6.5614 117.1842 181.5874 Tm
(36)Tj
9.843 0 0 9.843 129.3732 177.222 Tm
[(Previous)-482(efforts)-486.8(have)-490.5(included)-483.7(whole)-485.7(in-)]TJ
-6.8425 -1.1174 TD
[(activated)-228.1(virus)-224.3(or)-226.8(recombinant)-224.4(proteins)-228.9(\(gp120\).)-224.2(Conversely,)]TJ
0 -1.1116 TD
[(more)-340.8(recent)-344.3(approaches)-343.8(included)-345.5(vectors)-338.2(such)-345.2(as)-337.2(DNA,)-343.4(re-)]TJ
T*
[(combinant)-319(virus,)-314.1(such)-316.4(as)-314.2(canary)-315.3(pox)-314.3(\(ALVAC\))-317.8(or)-313.2(adenovi-)]TJ
0 -1.1174 TD
[(rus,)-386.6(or)-382.3(antigen-loaded)-383.3(dendritic)-387(cells;)-389.3(the)-384.7(latter)-383.7(resulted)-385.5(in)]TJ
0 -1.1116 TD
[(prolonged)-258.8(viral)-260.3(control)-256.8(of)-255.6(up)-255.6(to)-255.8(48)-255.6(weeks)-261.9(and)-252.1(a)-261.4(drop)-252(in)-255.8(viral)]TJ
T*
[(load)-201.5(compared)-197.8(to)-198.2(pre-antiretroviral)-203.5(treatment.)]TJ
7.3823 0 0 6.5614 240.9448 115.8235 Tm
(36,37)Tj
9.843 0 0 9.843 259.4834 111.4582 Tm
[(Thus,)-198.9(with)]TJ
-20.0611 -1.1174 TD
[(the)-321.4(exception)-318.9(of)-318.9(the)-321.4(DC-based)-323.8(study,)-314.1(the)-321.4(majority)-322.6(of)-319(thera-)]TJ
0 -1.1116 TD
[(peutic)-475.7(vaccine)-473.3(approaches)-476.2(have)-479(shown)-472.7(limited)-471.4(prolonged)]TJ
T*
[(viral)-191.2(control,)-191.1(begging)-187.6(the)-188.9(question)-194.4(as)-187.5(to)-192.4(whether)-189.6(an)-187.7(exhausted)]TJ
0 -1.1174 TD
[(immune)-327.2(system)-331.3(will)-328.2(be)-325.9(able)-329.4(to)-330.6(induce)]TJ
/F9 1 Tf
16.0062 0 TD
[(de)-331.7(novo)]TJ
/F4 1 Tf
3.5537 0 TD
[(immune)-327.1(re-)]TJ
-19.56 -1.1116 TD
[(sponses)-284.8(able)-283.3(to)-278.8(drive)-283.2(a)-278.7(functional)-284.4(cure.)]TJ
/F11 1 Tf
8.9663 0 0 8.9663 313.0582 725.7825 Tm
[(Natural)-341.2(killer)-332.1(cells)]TJ
/F4 1 Tf
9.843 0 0 9.843 323.0361 709.3416 Tm
[(Interestingly,)-383.2(beyond)-376.4(T)-382.4(cells,)-380(other)-375.4(innate)-383.6(immune)-379(cells)]TJ
-1.0137 -1.1116 TD
[(have)-202.6(also)-195.6(been)-196.8(considered)-198.7(as)-199(potential)-197.1(target)-199.2(effector)-196.6(cells)-198(for)]TJ
0 -1.1174 TD
[(a)-411.2()50.8(shock)-405(and)-407.6(kill)51.7()-410(strategy,)-406.3(including)-408.9(natural)-407.7(killer)-411.3(\(NK\))]TJ
0 -1.1116 TD
[(cells,)-201.4(due)-194.5(to)-192.4(their)-197(inherent)-195.7(cytolytic)-197.1(capacity)-198(in)-192.4(the)-194.7(absence)-196.5(of)]TJ
T*
[(any)-280.9(requisite)-277.4(antigen)-275.2(sensitization.)]TJ
7.3823 0 0 6.5614 450.4818 669.8833 Tm
(38)Tj
9.843 0 0 9.843 460.6298 665.5179 Tm
[(These)-273.8(strategies)-279.4(aim)-276.5(to)]TJ
-14.9925 -1.1174 TD
[(take)-404.3(advantage)-406.4(of)-399.6(the)-402(natural)-401.9(stress)-404.7(ligands)-400.6(\()-87.5(MHC)-397.8(class)-405(I)]TJ
0 -1.1116 TD
[(polypeptide)-9.1(-related)-231.4(sequence)-226.4(A-MICA,)-232.5(MICB,)-229.7(or)-226.8(the)-229.2(UL16-)]TJ
T*
[(binding)-203.8(protein)-204.9(1ULBP1,)-205.3(ULBP2,)-207.7(or)-198(ULBP3\))-205.4(that)-207.4(activate)]TJ
T*
[(NK)-384.1(cell)-387.1(killing)-382.6(through)-382.2(a)-382.4(dominant)-385.8(activating)-383.6(NK)-384.1(cell)-381.4(re-)]TJ
0 -1.1174 TD
[(cepto)-8(r,)-292.5(NKG2D,)-300.4(critically)-303.1(implicated)-304.2(in)-296.1(tumor)-300.6(cell)-300.7(elimina-)]TJ
0 -1.1116 TD
(tion.)Tj
7.3823 0 0 6.5614 330.9164 604.1195 Tm
(3941)Tj
9.843 0 0 9.843 351.8928 599.7542 Tm
[(Howev)-8.4(er,)-254.4(as)-250.8(in)-255.8(the)-258(setting)-256.7(of)-249.8(tumors,)-258.9(subjects)-258.7(with)]TJ
-3.9454 -1.1116 TD
[(HIV)-500.3(exhibit)-493.1(high)-499.9(levels)-492.8(of)-497.5(serum)-497.2(MICA,)-494.4(which)-497.2(reduces)]TJ
0 -1.1174 TD
[(NKG2D)-412.2(expression)-404.7(on)-405.4(systemic)-409.7(NK)-407.1(cells,)-408.8(resulting)-408.7(in)-399.7(at-)]TJ
0 -1.1116 TD
[(tenua)-8(ted)-350.2(NKG2D-mediated)-363.7(activation)-360.6(of)-353.5(NK)-355.3(cells,)-356.9(even)-352.3(in)]TJ
T*
[(the)-476.9(settin)-8(g)-473.4(o)0(f)-474.5(long-term)-479(HAART)-482.7(treatment.)]TJ
7.3823 0 0 6.5614 495.8361 560.2959 Tm
(42)Tj
9.843 0 0 9.843 507.9117 555.9305 Tm
[(Thus,)-481.1(HIV)]TJ
-19.7961 -1.1174 TD
[(infection)-317.9(may)-305.2(result)-313.1(in)-313.4(an)-308.6(irreversible)-316.3(defect)-309.7(in)-307.6(NK)-315(cell)-312.3(ac-)]TJ
0 -1.1116 TD
[(tivity,)-189.1(which)-192(may)-190(limit)-185.8(the)-188.9(utility)-186.9(of)-192.2(these)-186.3(innate)-193.5(effector)-190.9(cells)]TJ
T*
[(in)-284.6(direct)-279.9(recognition)-285.5(and)-280.9(lysis)-281.8(of)-278.6(reactivated/infected)-291.2(cells.)]TJ
/F11 1 Tf
8.9663 0 0 8.9663 313.0582 498.1038 Tm
[(Monoclonal)-337.8(antibodies)]TJ
/F4 1 Tf
9.843 0 0 9.843 323.0361 481.6629 Tm
[(Conversely,)-599.4(beyond)-595.3(direct)-602.4(cellular-based)-603.1(mechanisms,)]TJ
-1.0137 -1.1116 TD
[(antibodies)-249.7(\(Abs\))-242.3(are)-241.7(also)-241.6(able)-243(to)-238.5(induce)-245.2(the)-240.7(rapid)-242.9(destruction)]TJ
T*
[(of)-198(material)-192.4(to)-192.4(which)-197.7(they)-195.8(are)-189.9(bound)-195.6(by)-192.3(directing)-196.9(the)-194.7(cytotoxic)]TJ
T*
[(and)-396.1(antiviral)-392.9(activity)-391.8(of)-393.8(the)-390.5(innate)-389.3(immune)-396.3(system.)-392.3(More-)]TJ
0 -1.1174 TD
[(over,)-291.2(this)-286.7(immunological)-290.3(activity)-293.9(has)-286.5(been)-289(widely)-291.1(exploited)]TJ
0 -1.1116 TD
[(by)-290.2(the)-286.8(monoclonal)-285.5(antibody)-292.5(\(mAb\))-284(therapeutics)-294.5(community)]TJ
T*
[(for)-343.1(the)-338.7(rapid)-340.8(and)-344.3(effective)-343.1(clearance)-345.3(of)-342(tumor)]TJ
7.3823 0 0 6.5614 498.5006 420.3211 Tm
(4345)Tj
9.843 0 0 9.843 520.3274 415.9558 Tm
[(or)-342(auto-)]TJ
-21.0575 -1.1174 TD
[(immune)-304.1(cellular)-300.6(targets.)]TJ
7.3823 0 0 6.5614 409.8896 409.3794 Tm
(46)Tj
9.843 0 0 9.843 420.2078 404.9574 Tm
[(This)-293.5(large)-301.7(body)-298.2(of)-295.9(literature)-302.9(pro-)]TJ
-10.8858 -1.1116 TD
[(vides)-334.9(critical)-335.3(strategic)-336.1(insights)-337.1(into)-333(how)-332.5(a)-330.6(similar)-332.8(approach)]TJ
T*
[(can)-449.1(be)-446.9(developed)-445.5(for)-446.7(HIV)-448.5(eradication.)-446.8(Importantly,)-450.2(these)]TJ
0 -1.1174 TD
[(monoclonal)-297.1(therapeutics)-294.5(mediate)-294.9(their)-289.1(lytic)-289.3(activity)-293.9(through)]TJ
0 -1.1116 TD
[(the)-546(recruitment)-552.8(of)-543.6(specic)-546.6(sets)-546.7(of)-543.6(innate)-544.8(immune)-546(cells,)]TJ
T*
[(throug)-6.7(h)-317.9(F)0(c)-325.7(receptors,)-327.7(complement,)-325.9(or)-324.7(lectin-like)-327.2(innate)-326(im-)]TJ
T*
[(mune)-254.5(receptors,)-258.6(aimed)-256.9(at)-251.2(rapidly)-256.8(and)-252.1(effectively)-259(eliminating)]TJ
0 -1.1174 TD
[(target)-418.1(cells)-411.1(throughout)-408.7(the)-413.5(body.)-411(Therefore,)-415.4(a)-411.2(mAb)-408.6(thera-)]TJ
0 -1.1116 TD
[(peutic)-268.4(strategy)-270.4(may)-264.9(contribute)-267.1(to)-261.5(the)-269.5()50.8(kill)50.7()-266(i)0(n)-261.5(a)-267.2()50.8(shock)-266.7(and)]TJ
T*
[(kill)46()-191.1(strate)-9(gy)-192.3(to)-192.4(support)-197.7(T)-192.4(cell-mediated)-200.4(clearance)-201.3(or)-192.2(offer)-196.6(an)]TJ
0 -1.1174 TD
[(alternative)-288(strategy)-281.9(to)-284.6(drive)-277.5(a)-284.5(functional)-284.4(cure)-283.2(\(Fig.)-278.5(1\).)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 313.0582 270.2551 Tm
[(Viral)-338.9(Protein)-336.1(Targets)]TJ
/F4 1 Tf
9.843 0 0 9.843 323.0361 253.8708 Tm
[(Like)-352.5(T)-347.9(cell)-346.8(escape,)-348.6(which)-353.3(may)-345.5(limit)-352.8(the)-344.4(utility)-348.2(of)-347.7(CD8)]TJ
/F7 1 Tf
7.3823 0 0 6.5614 548.2203 258.2361 Tm
(+)Tj
/F4 1 Tf
9.843 0 0 9.843 313.0582 242.8724 Tm
[(T)-417(cell-mediated)-419.3(viral)-410.1(eradication)-420.3(strategies,)-415.3(the)-413.5(virus)-414.3(may)]TJ
0 -1.1116 TD
[(have)-381.1(historically)-384.6(also)-379.9(escaped)-380.8(antibody)-378.9(\(Ab\)-mediated)-388.7(im-)]TJ
T*
[(mune)-484.9(pressure.)-486.4(However,)-481.7(a)-480.3(mAb)-483.5(footprint)-482.5(is)-480.2(remarkably)]TJ
0 -1.1174 TD
[(different)-283.1(from)-282(one)-280.9(targeted)-283.2(by)-278.7(a)-278.7(T)-284.5(cell,)-281.1(which)-278.4(may)-282.2(be)-279.8(much)]TJ
0 -1.1116 TD
[(larger,)-375.3(broader,)-376.3(and)-367.3(more)-375.4(exible)-373(in)-365.2(binding)-376.6(to)-365.2(its)-372(epitope)]TJ
T*
[(even)-398.4(in)-388.2(the)-396.3(setting)-395(of)-393.8(escape.)-394.6(Many)-392.4(neutralizing)-397.3(and)-396.1(non-)]TJ
0 -1.1174 TD
[(neutralizin)-10.3(g)-617.4(HIV-specic)-621.8(monoclonals,)-623.9(targeting)-623.1(diverse)]TJ
0 -1.1116 TD
[(areas)-429.2(of)-422.6(the)-419.3(virus,)-423.5(have)-427.2(now)-418.9(been)-427.2(cloned)-423.8(that)-420.5(cover)-428.3(HIV)]TJ
T*
[(strains)-342.8(with)-333.8(remarkable)-345.3(breadth,)-336.1(via)-338.7(the)-332.9(targeting)-340.9(of)-336.2(highly)]TJ
0 -1.1174 TD
[(conserved)-560.4(epitopes)-558.4(across)-555.7(global)-555.2(viral)-554.1(quasispecies.)-562.4(Im-)]TJ
0 -1.1116 TD
[(portantly,)-222.2(the)-223.5(selection)-220.9(of)-221(the)-217.7(best)-218.6(mAb)-224.3(or)-215.3(mAb)-218.5(cocktail)-225.8(may)]TJ
T*
[(not)-400.9(depend)-400.6(only)-396.2(on)-393.9(the)-402(mAbs)-393.3(capacity)-405.4(to)-394(recognize)-406.3(HIV)]TJ
T*
[(broadly,)-427.1(but)-418.1(may)-420.4(also)-420.2(relate)-425(to)-417(the)-425.1(kinetics)-420.3(of)-422.6(the)-419.3(mAbs)]TJ
0 -1.1174 TD
[(epitope)-286.8(expression)-283.8(on)-278.7(infected)-283.2(cells.)]TJ
1.0137 -1.1116 TD
[(The)-345.5(mature)-344.3(HIV-1)-347(envelope)-340.7(\(Env\))-346.5(spike)-340.7(is)-342(composed)-346.2(of)]TJ
-1.0137 -1.1116 TD
[(trimeric)-421.6(surface)-419.9(gp120)-420.2(that)-414.8(is)-416.8(noncovalently)-421.4(bound)-420.2(to)-417(tri-)]TJ
0 -1.1174 TD
[(meric)-228(transmembrane)-222.9(gp41.)-221(Importantly,)-225.6(while)-220.9(the)-223.5(emerging)]TJ
0 -1.1116 TD
[(Env)-465.3(spike)-461.6(rst)-464.9(appears)-466(on)-463(the)-465.4(cell)-462(surface)-466(as)-463.9(a)-463(trimer,)]TJ
7.3823 0 0 6.5614 544.8187 60.9449 Tm
(47)Tj
/F3 1 Tf
8.9663 0 0 8.9663 62.022 749.6502 Tm
(14)Tj
45.1266 0 TD
[(EULER)-335.9(AND)-337.2(ALTER)]TJ
ET
endstream
endobj
77 0 obj
<>stream
/GS1 gs
BT
/F4 1 Tf
9.843 0 0 9.843 59.7543 527.8109 Tm
0 0 0 1 k
0 Tc
0 Tw
[(several)-356.7(lines)-352.3(of)-353.5(evidence)-359.2(suggest)-354.2(that)-351.4(Env)-350.1(epitopes)-356.8(are)-351.2(ex-)]TJ
0 -1.1116 TD
[(posed)-213.8(at)-210.8(different)-214(times)-209.6(during)-208.3(Env)-211.8(maturation)-210.8(on)-209.5(the)-211.9(surface)]TJ
T*
[(of)-336.2(virion-producing)-335.9(cells)-342(and)-332.8(on)-336.3(the)-332.9(surface)-339.2(of)-336.2(released)-335.9(vi-)]TJ
0 -1.1174 TD
(rions.)Tj
7.3823 0 0 6.5614 81.9212 499.351 Tm
(4749)Tj
9.843 0 0 9.843 102.6708 494.929 Tm
[(These)-233.5(changes)-229.9(in)-227(exposed)-234.5(structures)-232(are)-230.2(related)-230.3(to)]TJ
-4.3601 -1.1116 TD
[(the)-183.1(transient)-185.2(association)-188.4(of)-180.7(the)-183.1(trimeric)-185.5(complex)-184.2(as)-181.7(well)-179.5(as)-181.7(the)]TJ
T*
[(transient)-288.9(nature)-285.5(of)-278.6(the)-286.8(association)-286.3(between)-288.7(gp120)-282(and)-280.9(gp41,)]TJ
0 -1.1174 TD
[(resulting)-431.7(in)-428.5(the)-425.1(production)-432.9(of)-422.6(variable)-433(amounts)-430.5(of)-428.4(trimer,)]TJ
0 -1.1116 TD
[(monomer,)-366.1(and)-367.3(gp41)-367.3(alone)-365.1(on)-365.1(the)-367.5(surface)-368(of)-365(infected)-363.9(cells.)]TJ
T*
[(Thus,)-469.6(it)-469(is)-462.9(likely)-468.9(that)-466.6(differences)-471.6(in)-468.9(epitope)-471.1(exposure)-465.9(on)]TJ
T*
[(the)-188.9(surface)-183.7(of)-180.7(virion-produ)-7.6(cing)-178.5(cells)-186.4(are)-184.1(directly)-190(related)-184.2(to)-180.9(the)]TJ
0 -1.1174 TD
[(kinetics)-403(of)-393.8(the)-402(structure)-398.1(of)-399.6(the)-396.3(HIV)-396.7(Env)-401.9(expressed)-398.9(on)-393.9(the)]TJ
0 -1.1116 TD
[(surface)-414.1(of)-405.3(infected)-409.9(cells)-411.1(over)-403(the)-407.8(course)-411.9(of)-405.3(cellular)-410.1(infec-)]TJ
T*
(tion.)Tj
7.3823 0 0 6.5614 77.6126 400.7054 Tm
(5052)Tj
9.843 0 0 9.843 99.0425 396.3401 Tm
[(Specically,)-302.5(early)-301.7(after)-301.6(infection,)-304(as)-296.9(virions)-301.5(begin)]TJ
-3.9915 -1.1174 TD
[(to)-376.7(assemble)-376.1(and)-378.8(release)-375.1(from)-374.2(the)-373.2(surface)-379.6(of)-376.5(cells,)-374.2(surface-)]TJ
0 -1.1116 TD
[(exposed)-292.1(Env)-292.5(proteins)-292.2(are)-287.8(likely)-290.4(mostly)-295.9(present)-292.2(in)-284.5(a)-290.2(trimeric)]TJ
T*
[(form)-282(prior)-282(to)-278.8(virion)-283.3(release.)]TJ
7.3823 0 0 6.5614 170.3621 367.8235 Tm
(47)Tj
9.843 0 0 9.843 69.7323 352.4597 Tm
[(By)-256.7(contrast,)-256.5(as)-256.6(cells)-255.6(become)-259(exhausted,)-258.7(due)-257.9(to)-255.8(large-scale)]TJ
-1.0137 -1.1116 TD
[(virion)-277.5(production,)-275(the)-269.5(remaining)-278.6(unincorporated)-272.5(Envs)-276.1(likely)]TJ
T*
[(dissociate)-262.2(into)-252.3(monomeric)-256.7(Envs)-253.1(and)-257.9(gp41)-252.1(alone,)-259.1(resulting)-253.1(in)]TJ
T*
[(an)-233.7(accumulation)-232.6(of)-226.8(nonfunctional)-235.9()50.8(spikes)47.9()-225.7(o)0(n)-232.6(the)-229.2(surface)-229.8(of)]TJ
0 -1.1174 TD
[(the)-338.7(cell)-341.1(\(Fig.)-336.1(2\).)-333.9(Furthermore,)-341.5(the)-338.7(natural)-338.6(ligand)-336.3(for)-337.3(Env)-338.6(is)]TJ
0 -1.1116 TD
[(CD4,)-193(which)-186.2(when)-190.8(bound)-189.8(results)-187.3(in)-186.6(conformational)-193.3(changes)-189.6(in)]TJ
T*
[(the)-281.1(epitopes)-287.7(exposed)-280.6(on)-278.7(gp120.)]TJ
1.0137 -1.1174 TD
[(The)-518.3(CD4)-517.8(expression)-519.9(levels,)-513.5(in)-514.9(cis,)-520.4(can)-518.2(therefore)-514.5(pro-)]TJ
-1.0137 -1.1116 TD
[(foundly)-474.3(modify)-480.2(the)-471.1(epitopes)-477.7(expressed)-479.5(on)-474.5(a)-474.6(given)-473.3(target)]TJ
T*
[(cell,)-477(resulting)-477.8(in)-468.9(the)-476.9(exposure)-477.4(of)-474.5(CD4-inducible)-473.9(epitopes)]TJ
0 -1.1174 TD
(\(CD4i\).)Tj
7.3823 0 0 6.5614 90.1417 247.2944 Tm
(52,53)Tj
9.843 0 0 9.843 109.8141 242.8724 Tm
[(Thus,)-308.3(while)-313.1(the)-309.9(most)-310.8(potent)-307.5(neutralizing)-316.7(mAbs)]TJ
-5.0858 -1.1116 TD
[(will)-195.7(recognize)-199(the)-194.7(earliest)-202.5(infected)-196.8(cells,)-195.6(mAbs)-196.4(that)-195.9(recognize)]TJ
T*
[(gp41)-361.5(alone)-365.1(may)-362.8(mark)-363.9(a)-359.4(greater)-368.4(number)-360.3(of)-365(cells)-365(for)-360.3(longer)]TJ
0 -1.1174 TD
[(periods)-584.7(of)-578.1(time,)-586.5(as)-579.1(gp120)-581.5(molecules)-584.9(dissociate)-584.7(readily,)]TJ
0 -1.1116 TD
[(leaving)-367.4(gp41)-361.5(stumps)-364.7(on)-359.3(the)-367.5(surface)-362.3(of)-365(cells.)-362.7(Therefore)-365.8(the)]TJ
T*
[(ultimate)-260.5(selection)-255.5(of)-255.6(the)-252.3(optimal)-258.2(mAb\(s\))-256.1(for)-256.7(eradication)-259(will)]TJ
T*
[(likely)-394.1(be)-389.3(guided)-388(by)-388.1(the)-390.5(HIV-envelope)-398.7(targets)-390.2(that)-391.7(may)-385.8(be)]TJ
0 -1.1174 TD
[(differentially)-353.5(enriched)-352.2(on)-342(the)-350.2(surface)-350.8(of)-347.7(cells)-347.7(following)-345.2(re-)]TJ
0 -1.1116 TD
(activation.)Tj
1.0137 -1.1116 TD
[(Beyond)-348.6(Env-specic)-356.4(targeting)-352.4(approaches,)-352.9(a)-347.8(few)-350.9(studies)]TJ
-1.0137 -1.1174 TD
[(have)-496.3(observed)-494.7(an)-492.9(enrichment)-494(of)-497.5(HIV)-488.8(Gag-sp)-8.4(ecic)]TJ
7.3823 0 0 6.5614 272.4094 137.6504 Tm
(54)Tj
9.843 0 0 9.843 284.5983 133.285 Tm
(and)Tj
-22.843 -1.1116 TD
[(other)-507.9(regulatory/acces)-13.2(sory)-505.3(protein-specic)-510.7(antibodies)]TJ
7.3823 0 0 6.5614 278.8157 126.7086 Tm
(55)Tj
9.843 0 0 9.843 291.1747 122.3433 Tm
(in)Tj
-23.5111 -1.1116 TD
[(subjects)-235.6(who)-228.8(durably)-233.6(control)-233.7(HIV)-229.6(infection)-237.2(in)-227(the)-235(absence)-231(of)]TJ
0 -1.1174 TD
[(therapy.)-255.5(These)-250.7(antibodies)-255.4(against)-252(non-Env)-250.8(targets)-252(have)-254.4(been)]TJ
0 -1.1116 TD
[(shown)-340.3(to)-342.1(mediate)-341(ADCC.)]TJ
7.3823 0 0 6.5614 164.2393 93.8268 Tm
(5558)Tj
9.843 0 0 9.843 186.0094 89.4614 Tm
[(Yet,)-343(because)-346.2(Gag)-339.4(is)-336.2(not)-337.5(ex-)]TJ
-12.8269 -1.1116 TD
[(pressed)-263(on)-261.4(the)-258(surface)-258.6(of)-261.4(infected)-260.2(cells,)-264.8(it)-255.9(is)-261.3(unclear)-259(whether)]TJ
T*
[(these)-267(antibodies)-267(contribute)-267.1(to)-267.3(direct)-262.6(lysis)-270.3(of)-261.4(infected)-266(cells)-267.1(or)]TJ
0 -1.1174 TD
[(whether)-327.8(these)-324.5(antibodies)-324.6(act)-322.5(as)-325.7(surrogates)-324(of)-319(a)-324.8(more)-323.5(potent)]TJ
25.5097 47.8747 TD
[(humoral)-447.9(immune)-448.1(prole.)-448.9(Along)-450(these)-451.3(lines,)-447.9(subjects)-454.5(who)]TJ
0 -1.1116 TD
[(selectively)-489.4(generate)-491.6(elevated)-486(Gag-specic)-489.7(antibodies)-491.6(also)]TJ
T*
[(generate)-278.5(the)-281.1(more)-277.5(abundant)-276.2(gp120-)-277.3(IgG3)-281.7(antibody)-275.2(subclass,)]TJ
0 -1.1174 TD
[(known)-231(to)-238.5(have)-237.1(the)-235(greatest)-237(antiviral)-237.4(activity.)-239.7(Nevertheless,)-240.9(if)]TJ
0 -1.1116 TD
[(expressed)-220.3(on)-215.3(the)-217.7(infected)-219.9(cell)-214.3(surface,)-221.7(additional)-221.2(viral)-214.2(targets)]TJ
T*
[(may)-408.9(represent)-410.7(additional)-411.3(targets)-407.5(for)-412.2(the)-407.8(eradication)-408.8(of)-411.1(the)]TJ
0 -1.1174 TD
[(reactivated)-283.2(reservoir.)]TJ
1.0137 -1.1116 TD
[(Interestingly,)-325.6(HDACi-mediated)-329.4(reactivation)-323.6(is)-324.7(associated)]TJ
-1.0137 -1.1116 TD
[(with)-431.8(the)-430.8(transcription)-437.4(of)-428.4(detectable)-437.7(levels)-435.2(of)-428.4(RNA)-432.3(within)]TJ
T*
[(primary)-344.2(cells)]TJ
7.3823 0 0 6.5614 363.6282 433.5873 Tm
(14)Tj
9.843 0 0 9.843 374.3999 429.2219 Tm
[(and)-350(the)-344.4(release)-346.3(of)-347.7(infectious)-347.6(virions.)]TJ
7.3823 0 0 6.5614 522.1983 433.5873 Tm
(6,8,15,20)Tj
9.843 0 0 9.843 310.8472 418.2235 Tm
[(Because)-554.6(the)-546(production)-553.8(of)-549.3(virions)-549.2(requires)-552.4(viral)-548.3(protein)]TJ
ET
q
1 i
124.554 732.245 m
485.121 732.245 l
485.121 609.675 l
124.554 609.675 l
W n
q
360.926 0 0 122.57 124.554 609.675 cm
/Im1 Do
Q
Q
BT
/F5 1 Tf
9.845 0 0 9.845 59.7543 592.8943 Tm
[(FIG.)-428.9(1.)]TJ
/F4 1 Tf
4.2095 0 TD
[(Shock)-426.3(and)-424.5(kill)-424.9(approach)-426(to)-428.3(eliminate)-423.1(latently)-431.3(infected)-426.4(cells)-427.8(using)-425.3(antibody-targeted)-431.1(killing.)-425.6(Resting,)-427.3(latently)]TJ
-4.2095 -1.0135 TD
[(infected)-265.2(CD4)]TJ
/F7 1 Tf
7.3837 0 0 6.5625 114.0094 587.3384 Tm
(+)Tj
/F4 1 Tf
9.845 0 0 9.845 121.8897 582.9164 Tm
[(T)-261.3(cells)-260.8(can)-258.7(be)-262.3()50.8(shocked)46.5()-260.1(b)0(y)-255.4(various)-261.5(latency)-264.2(reversal)-264.8(agents)-261.7(\(LRA\).)-258.9(This)-258.5(will)-264.4(lead)-259.9(to)-261.3(the)-257.7(expression)-259.7(of)-261.1(viral)]TJ
-6.3114 -1.0077 TD
[(RNA)-299.3(and)-292.1(proteins,)-294.8(including)-292.8(expression)-294.2(of)-289.9(Env)-297.8(on)-289.9(the)-292.2(infected)-294(cell)-294.6(surface.)-295.8(Exogenously)-295.4(administered)-299.1(antibodies)-294.8(directed)]TJ
0 -1.0135 TD
[(against)-280.1(epitopes)-275.3(on)-272.6(Env)-274.8(will)-276(then)-276(recruit)-274.5(various)-273(innate)-279.3(effector)-276.5(cells)-278.1(to)-272.8(kill)-275.1(off)-273.6(infected)-276.7(cells)-278.1(in)-272.8(the)-275(presence)-277.3(of)-272.6(HAART)-280.2(to)]TJ
T*
[(prevent)-337.7(further)-336.5(infections.)]TJ
ET
q
238.023 0 0 218.098 311.414 172.8 cm
/Im2 Do
Q
BT
/F5 1 Tf
9.845 0 0 9.845 310.8472 156.0189 Tm
[(FIG.)-688(2.)]TJ
/F4 1 Tf
4.4686 0 TD
[(Potential)-685.5(forms)-691.2(of)-687.3(Envelope)-691.1(on)-681.5(the)-689.6(HIV-1-)]TJ
-4.4686 -1.0077 TD
[(infected)-340(cell)-334.9(membrane.)-339.6(Gp41)-333(and)-338.1(gp120)-333.2(are)-339.3(shown.)-337.2(From)]TJ
/F9 1 Tf
0 -1.0135 TD
[(left)-368.4(to)-364.9(right)]TJ
/F4 1 Tf
4.7508 0 TD
[(:)-364(gp120/gp41)-367.1(monomers)-368.3(begin)-363.3(to)-364.9(form)-367.9(less)-367.8(tri-)]TJ
-4.7508 -1.0135 TD
[(mers)-495.6(in)-491.6(mid-infection;)-496.2(naked)-496.8(gp41)-493.4(after)-496.9(gp120)-494.4(shedding)]TJ
T*
[(may)-425.7(occur)-433.4(during)-426.5(late)-432.8(stage)-427.7(infection;)-433.3(functional)-427.4(Env)-430.3(tri-)]TJ
0 -1.0077 TD
[(mers)-276.8(form)-275.8(early)-278.1(in)-272.8(cellular)-282.6(viral)-277.1(infection)-276.7(exposing)-279.7(epitopes)]TJ
0 -1.0135 TD
[(for)-394.6(neutralizing)-401.9(antibodies;)-393.8(Env)-395.7(trimers)-401(interact)-397.8(with)-396.7(CD4)]TJ
T*
[(on)-278.4(virally)-285(infected)-282.4(cells)-283.9(that)-281.9(change)-285.9(the)-280.7(conformation)-280.6(of)-284.1(the)]TJ
0 -1.0077 TD
[(trimer)-722.7(exposing)-723.1(CD4-induced)-729.3(nonneutralizing)-727.4(epitopes;)]TJ
0 -1.0135 TD
[(V1V2)-379.9(move)-380.6(to)-376.5(the)-378.6(side,)-382.8(exposing)-377.6(V3)-382.9(and)-378.4(the)-378.6(HR1)-379.1(region)]TJ
T*
[(from)-333.4(gp41.)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 59.7543 749.7069 Tm
[(MONOCLONAL)-336.8(ANTIBODIES)-339(FOR)-334(HIV)-339.4(ERADICATION)-28072.7(15)]TJ
ET
endstream
endobj
79 0 obj
<>stream
Adobe d C
s !1AQa"q2B#R3b$r%C4Scs5D'6Tdt&
EFVU(eufv7GWgw8HXhx)9IYiy*:JZjz ? Nlٳf͛6lٳf͛6lٳf͛9$Jr(v2 ]FI@^jRBM|sKAZ6F/n|;HdTY`pOLs~Z_0&BXiMg^JR]QNd mSN//G
/E+tday+M<.itnN59-)[Cm<ʲ=kɘ ~lJZN=[bWd{RJ:<_h*# 1yGTm,ntQmKyEp<JUצɣyαykm/3v7̏&Åߕ~q5{=nT1LQmbs']C4:8n|S]tٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳfmzIzypw%mimi
f8
[E\}m2DN(Z/<^Zڣ_\]y*NtDaz-p]揠KGZI"g4QDlZ]+Kڙlذk"z,b|8ys2&h^:3yVR3N5&q@%]q~i"iPY$dmH-Oyf͛6lٳf͛6lٳf͛6lٳf́=B;OYB쑎Nj+3 6UaPw3a^/TRt,LL~?T僯/'eeEƊ*
-6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳ ߘ>S#hx2J$;T5/aaţMY8{vlٳf͛6lٳf͛6lٳf͛6lٳf͍dhcn!AX63 ~pXm*D
hSw@uNX~z/-t0ɨnW&"cp|)__\jµM>ʀ:BzFi[Ȅ^- bkr1